Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Rising in COVID Times: A True Nevada Cannabis Success Story

(Oasis Cannabis Dispensary. Las Vegas, NV. Image via CLS Holdings.) Nevada’s cannabis industry is booming. Deemed an essential service in response to the COVID-19 pandemic, companies operating in this marketplace have seen impressive growth this ye...
Stockhouse Editorial | September 17, 2020 |

BioHarvest Sciences – Growing Exponentially

BioHarvest Sciences (CSNX: BHSC) is a rising star in the food, nutraceutical and cannabis industries. Through its intellectual property, it has developed a shortcut that could lead to cost savings and larger gross margins for its partners and future clients as well as a ...
Dr. Kal Kotecha | October 2, 2020 |

Buzz on the Bullboards: Market rebound in 2024?

The end of the year is fast approaching but that doesn’t mean the markets have slowed down as the holidays quickly approach. Over the past five-day period, the S&P/TSX Composite has increased by 23 points to 20,862.86, while the S&P/TSX Venture Composi...
Jocelyn Aspa | December 21, 2023 |

GlucoTrack: Company Addresses the Diabetes Testing and Monitoring Conundrum

GlucoTrack ( NDAQ:GCTK ) is an American medical device company focused on design, development and commercialization. The company is developing proprietary painless and non-invasive blood glucose monitoring devices for both Type 2 diabetes and prediabetes, a market almost ...
Simon Druker | January 16, 2023 |

ICAN Leverages Leading California Brand with Expansion into Nevada, ...

ICAN Leverages Leading California Brand with Expansion into Nevada, Introduces State-of-the-Art Pre-Roll Machine, for Aggressive Near-Term Growth A recent acquisition is helping this company to expand its brand. If a customer at any of the popular recreational ...
Streetwise Reports | November 21, 2019 |

Global Central Banks Move To Keep The Party Rolling Onward – Part I

The recent news that the US Fed, China and many of the global central banks are continuing to make efforts to lower rates and spark further consumer spending and economic activity is reminiscent of the late 2010~2013 global economic recovery efforts. This was a time when the e...
Chris Vermeulen | August 14, 2019 |

ES Must Hold Above 2800 Or The Selling Will Intensify

First off, we were so happy to hear from all of our followers over the weekend and early today regarding their support for our incredible market predictions – specifically the call about the August 19 th breakdown prediction. We stuck to our guns believing in our predictive m...
Chris Vermeulen | August 26, 2019 |

Rating, Target Upgraded on Gold Mining Major Undergoing a Turnaround

The reasons to be optimistic about this company are covered in a BMO Capital Markets report. In a Sept. 11 research note, analyst Andrew Kaip reported that his firm BMO Capital Markets upgraded its rating to Outperform and raised its target price to $50 per share from...
Streetwise Reports | September 18, 2019 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Feb 27th 2020, Crypto Chartbook – Expectations in check

Expectations in check If you compare the average performance of all major hedge funds from 1994 to 2018 you will find them underperforming the S&P by more than 2 percent. These funds cut volatility risk compared to the index by about half. However, you still can get hit h...
Korbinian Koller | February 27, 2020 |
1 2 3